nannamom
Admin
Number of posts : 2210
Age : 66
Humor : Once you choose hope, anything’s possible. -Christopher Reeve
Registration date : 2008-11-09
 | | Subject: Company announces plans to develop medication for Cocaine addiction Sun 22 May 2011, 12:32 am | |
| 
Alkermes, Inc has announced in its annual report that in April 2010 it announced plans for the development of ALKS 33 for the treatment of binge-eating disorder and as a combination therapy with buprenorphine for the treatment of cocaine addiction and mood disorders.
In October 2010 they announced positive topline results from a randomized, double blind, multi-dose, placebo controlled phase 1 clinical study that assessed the safety, tolerability and pharmacodynamic effects of the combination of ALKS 33 and buprenorphine when administered alone, and in combination, to 12 opioid experienced users. Data from the study showed that the combination therapy was generally well-tolerated and sublingual administration of ALKS 33 effectively blocked the agonist effects of buprenorphine. Based on those positive results, they expect to initiate a phase 2a study of the combination therapy for the treatment of cocaine addiction in midyear 2011.
The phase 2a study is expected to be funded through a grant from the National Institute on Drug Abuse (NIDA) NIDA has granted Alkermes, Inc. up to $2.4 million to accelerate the clinical development of the ALKS 33 and buprenorphine combination therapy. Currently there is no medications approved for the treatment of cocaine addiction.
For a full report please see the annual report from Alkermes, Inc.
Alkermes Annual Report | |
|
